EGFR (phospho-Y1148) polyclonal Antibody | BS4740

EGFR (phospho-Y1148) polyclonal Antibody | BS4740 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human,Mouse,Rat

Application: IHC

Application Range: IHC: 1:50~1:200

Background: Epidermal growth factor mediates its effects on cell growth through its interaction with a cell surface glycoprotein designated the EGF receptor. Binding of EGF or TGFα to the EGF receptor activates tyrosine-specific protein kinase activity intrinsic to the EGF receptor. The carboxy-terminal tyrosine residues on EGFR, Tyr 1068 and Tyr 1173, are the major sites of autophosphorylation, which occurs as a result of EGF binding. Once activated, EGFR mediates the binding of the phosphotyrosine binding (PTB) domain of GRB2 through direct interactions with Tyr 1068 and Tyr 1086 and through indirect interactions with Tyr 1173 in the Ras signaling pathway. Tyr 1173 of EGFR also functions as a kinase substrate. Phosphorylation of Tyr 992, Tyr 1068 and Tyr 1086 is required for conformational change in the C-terminal tail of the EGF receptorgulates Actin filament accumulation at the plasma membrane and Cdc42 stimulates formation of filopodia.

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: p-EGFR (Y1148) polyclonal Antibody detects endogenous levels of EGFR protein only when phosphorylated at Tyr1148 (removal of the signal peptide) .

Molecular Weight: ~ 175 kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: Epidermal growth factor receptor; EC=2.7.10.1; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1; ERBB; ERBB1; HER1; EGFR

Immunogen: Synthetic phosphopeptide derived from human EGFR around the phosphorylation site of Tyrosine 1148.

Conjugate: Unconjugated

Modification: Phosphorylation

Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway: